Abstract: The invention relates to a composition in the form of an oil-in-water emulsion, in particular a cosmetic and/or dermatological composition, comprising in a physiologically acceptable aqueous medium: a) at least Baicalin and/or one of the derivatives thereof or a plant extract containing it, b) at least one superabsorbent polymer, c) at least one homo- or copolymer of non-superabsorbent acrylic acid that is at least partially neutralized, and d) at least one gemini surfactant with formula (III), said composition having a p H of 6.0 to 6.5. The invention also relates to a cosmetic care and/or makeup method for keratin materials, comprising the topical application of a composition according to the invention on keratin materials.

Abstract: Nutritional compositions (e.g., dietary supplements or nutraceutical compositions) comprising astaxanthin and, in various embodiments, a second nutritional component selected from the group consisting of phospholipids, omega-3-acids, omega-5-fatty acids, omega-6-fatty acids, omega-7-fatty acids, omega-9-fatty acids, vitamin E compounds, and mixtures thereof. For example, the nutritional compositions may contain astaxanthin along with components such as omega-3 fatty acids, phospholipids comprising a major amount of phosphatidyl choline and phosphatidyl inositol, and vitamin E comprising a major amount of delta-tocotrienol. Methods of improving the nutritional status of subject include administering the nutritional compositions, and may provide health benefits, such as reducing A1C blood levels.

Abstract: Certain embodiments are directed to methods and compositions for treating obesity, diabetes, and/or cancer with a combination of ursolic acid and resveratrol.

Abstract: Certain embodiments are directed to methods and compositions for treating obesity, diabetes, and/or cancer with a combination of ursolic acid and resveratrol.

Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.

Abstract: Certain embodiments are directed to methods and compositions for treating obesity, diabetes, and/or cancer with a combination of ursolic acid and resveratrol.

Abstract: The present invention relates to new compositions suitable for use in the treatment of articular disorders (or conditions), processes for preparing said compositions and use of said compositions in therapeutic treatments of articular disorders.

Abstract: Systems and methods are provided framework for automatically choosing the appropriate generalized linear model (GLM) given a time series of count data, and for anomaly detection on time series data. A dispersion parameter is determined and used to determine whether the count data is overdispersed data or underdispersed data. The overdispersed data or the underdispersed data is used to determine a GLM to apply on the dataset. Using the determined GLM on the data, anomalies can be determined.

Abstract: Methods of treating patients having varicose veins, methods of identifying subjects having an increased risk of developing varicose veins, and methods of diagnosing varicose veins in a human subject, comprising detecting the presence of Piezo Type Mechanosensitive Ion Channel Component 1 (PIEZO1) predicted loss-of-function variant nucleic acid molecules and polypeptides in a biological sample from the patient or subject, are provided herein.

Abstract: The present invention relates to a method of reducing or preventing the symptoms associated with the intake of alcohol. The method comprises administering to a subject an effective amount of a pharmaceutical composition prior to alcohol intake. The pharmaceutical composition comprises a non-steroidal anti-inflammatory drug and a H1-antihistamine.

Abstract: Provided are compositions and methods for the identification and treatment of ovarian cancers, such as small cell ovarian cancers, in particular small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), which ovarian cancers are characterized by reduced SMARCA4 gene expression and/or protein function and, as a consequence, are sensitive to growth and/or survival inhibition by one or more compounds that restore SMARCA4 gene expression and/or protein function.

Abstract: The present disclosure provides methods and compositions for reducing the risk of pathological effects of traumatic brain injury.

Abstract: A method of treating haematological cancer with a therapy comprising a DHODH inhibitor. Also provided is a combination therapy comprising a pan-HER inhibitor and a DHODH inhibitor for treating a haematological cancer.

Abstract: An oral care composition including rottlerin in an amount sufficient to reduce a growth of gram-positive bacteria in a mouth treated with the oral care composition.

Abstract: Pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt of azelastine and folic acid or folate, and/or salts, metabolites, or derivatives thereof are disclosed. Methods of using the pharmaceutical compositions for treating patients suffering from one or more psychiatric disorders or symptoms, such as major depressive disorder, generalized anxiety disorder, panic disorder, agitation, social anxiety disorder, mild chronic depression, obsessive-compulsive disorder, premenstrual dysphoric disorder, seasonal affective disorder, dysthymia, bipolar disorder, posttraumatic stress disorder, sleep disorder related to anxiety, are also disclosed.

Abstract: A method and composition for treating viral infections using a combination of naturally occurring compounds is provided. The method includes administering to a patient at risk of or diagnosed with a viral infection a composition including therapeutically effective amounts of a helicase ATPase inhibitor, a sialidase enzyme inhibitor, an ICAM-1 inhibitor and gallic acid which each also down regulate the immune response. The composition may further include a permeation enhancer.

Abstract: The present specification relates to a whitening composition containing a novel quercetin-based compound isolated from post-fermented tea, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, wherein the whitening composition can be widely utilized in fields associated with skin whitening and skin care.

Abstract: A pathophysiological effect of a transient receptor potential cation channel, subfamily V, member 3 (TRPV3) on psoriasis, which can be used to develop a drug for preventing or treating psoriasis. The invention further discloses an application of Scutellarein as a TRPV3 inhibitor in preparing a drug for preventing or treating psoriasis. When a drug containing the TRPV3 inhibitor discovered according to the invention or provided by the invention is used for preventing or treating psoriasis, good prevention or treatment effects can be achieved.

Abstract: A composition containing L-arginine and a glycosyl compound of formula (I): in which R is a moiety formed of a monosaccharide, a disaccharide, or an oligosaccharide including three to five monosaccharides; and the composition contains the glycosyl compound and L-arginine in a molar ratio of 1:1.6 to 1:3.0. Also disclosed is a method for preparing such a composition, as well as a composition prepared by the method.

Abstract: Described herein are pharmaceutical compositions comprising one or more modulators of a cytochrome 450 enzyme (CYP450) and substituted or unsubstituted diindolylmethane. Also described herein are methods for treating one or more skin conditions by administering a combination therapy comprising substituted or unsubstituted diindolylmethane and one or more modulators of CYP450. In particular, methods are disclosed for improving bioavailability and pharmacokinetic parameters of substituted or unsubstituted diindolylmethane following the combination therapy.

Abstract: Various aspects of the present disclosure provide compositions including a water-insoluble therapeutic agent and a gallate-containing compound. Other aspects provide methods of using such compositions.

Abstract: The disclosure provides an oral antiviral supplement composition comprising a lysine, an ascorbic compound, a flavonoid glycoside, a threonine, and a pyridoxine. The disclosure also provides a method of reducing viral replication in a cell comprising treating a virus-infected cell with a composition of the disclosure. The disclosure further provides a method for the treatment and prophylaxis of a viral infection in a patient comprising administering a composition of the disclosure.

Abstract: A method and composition for providing hydrolyzed starch and fiber. In one aspect, the method comprises providing a first enzyme; a second enzyme; water; and a starting composition comprising at least one material selected from the group consisting of at least a portion of grain and at least a portion of pulse. Additional steps comprise hydrolyzing the fiber and starch in the at least one material through fiber and starch hydrolysis reactions catalyzed by the first and second enzymes, respectively. Further steps comprise deactivating the first and second enzymes. In a second aspect, a composition comprises at least one material selected from the group consisting of at least a portion of grain and at least a portion of pulse. The average molecular weights of the hydrolyzed starch and fiber molecules in the composition are fractions of the molecular weights of unhydrolyzed starch and fiber molecules, respectively.

Abstract: It is provided a treatment selection support system comprising: a target achievement determination module configured to create target achievement determination information; a blood sugar controllability estimation module configured to create blood sugar controllability information; an achievement level prediction model creation module configured to create an achievement level prediction model; an appropriateness level calculation model creation module configured to create an appropriateness level calculation model for calculating an appropriateness level of a blood sugar control means based on formatted information, the target achievement determination information, and the blood sugar controllability information; an achievement level prediction module configured to use the achievement level prediction model; an appropriateness level calculation module configured to use the appropriateness level calculation model; and a blood sugar control means suggestion module configured to provide information on the blood

Abstract: The present invention relates to compositions and methods for prophylactic and/or therapeutic treatment of conditions related to mitochondrial function. In various aspects, the present invention comprises administering one or more compounds selected from the group consisting of epicatechin, an epicatechin derivative, catechin, a catechin derivative, nicorandil, and a nicorandil derivative in an amount effective to ameliorate mitochondrial toxicity caused by administration of a chemical, food, or drug.

Abstract: The present disclosure provides methods and compositions for the prevention, amelioration, or alleviation of one or more neurological disorders associated with microbially-induced amyloid formation. Methods of inhibiting, ameliorating, reducing the likelihood, delaying the onset of, treating, or preventing an amyloid disorder are disclosed. Methods of identifying compounds capable of inhibiting the formation of microbially-induced amyloid fibrils are disclosed.

Abstract: Materials and methods for treating major depressive disorder by modulating the aryl hydrocarbon receptor system are provided herein.

Abstract: Personal care compositions including a naringin:zinc complex and methods for preparing and using the same are provided. The personal care compositions may include a carrier and a naringin:zinc complex having a 2:1 naringin to zinc molar ratio.

Abstract: An icariside compound as shown in Formula I wherein the compound is a natural chemical component in the traditional Chinese herbal epimedium or a chemically modified or a totally synthetic product based on the natural component. The compound can be used for preparing pharmaceuticals, health care products, cosmetic and skin care products and the like for improvement of immunity in a human body.

Abstract: The present invention discloses compounds for inhibition of uncontrolled cell proliferation particularly in cancer stem cells. Particularly, the invention relates to compounds of Formula III to XIV for the treatment of cancer, such as breast and prostate cancer.

Abstract: This disclosure provides compositions and methods for improving erythrocyte dysfunction or treating a hemoglobinopathy or a thalassemia (e.g., sickle cell disease or ?-thalassemia).

Abstract: Association comprising: —dry extract of: a) Vicia faba, b) Uncaria rhyncophylla and c) liquorice root, —coenzyme Q10, and preferably at least one vitamin chosen from vitamin C and E for use as coadjuvant for improving the quality of life (QOL) in subjects with movement disorders and in particular in subjects suffering from Parkinson's disease. This association is preferably in an oral formulation, more preferably in the form of a food supplement.

Abstract: The present disclosure provides miRNA mimics targeting CDK4 and/or CDK6, and compositions comprising the same. Methods for the treatment of tumors, including but not limited to colon cancer, comprising administering a modified oligonucleotide comprising a miRNA are also disclosed herein.

Abstract: A method and composition for treating viral infections using a combination of naturally occurring compounds is provided. The method includes administering to a patient at risk of or diagnosed with a viral infection a composition including therapeutically effective amounts of a helicase ATPase inhibitor, a sialidase enzyme inhibitor, and ICAM-1 inhibitor which each also down regulate the immune response. The composition may further include a permeation enhancer.

Abstract: Use of albiflorin or a pharmaceutically acceptable salt thereof in the preparation of a product for regulating and improving the balance of human intestinal flora. Albiflorin or a pharmaceutically acceptable salt thereof, as a regulator for improving the function of intestinal flora system, can be used in the preparation of a medicament, a health care product, a food, a food additive, or a nutritional supplement that ameliorates and treats a sub-health status and/or a disease caused by intestinal flora disturbance; the sub-health status is selected from intestinal system dysfunction and/or affective disorder; and the disease is selected from one or more of irritable bowel syndrome, depression, anxiety, colitis, and colon cancer.

Abstract: This invention relates to the use of an Aronia berry extract or a composition comprising said extract for enhancing the reaction time, attention, concentration and psychomotor control of a mammal, more in particular a human. The composition comprising the Aronia extract is formulated for oral ingestion.

Abstract: The present invention relates to a pharmaceutical composition or medical device comprising a fucoidan and at least one compound of formula A or B: wherein R1 and R2 are independently selected from the group consisting of —OH, —CH3, —CF3CH2O—, and CH3O—. Such pharmaceutical composition or medical device is notably useful for the treatment and/or prevention of a skin disorder involving excessive angiogenesis and/or fibrogenesis, such as in skin fibrosis, angiofibromas, hamartomas and periungual fibromas, skin manifestation occurring with rosacea, acne, atopic dermatitis, scleroderma, psoriasis and lupus erythematosus, and especially of Tuberous Sclerosis Complex and skin manifestation occurring with Tuberous Sclerosis Complex.

Abstract: The present invention discloses a composition comprising not less than 10% w/w of oroxylin A, not less than 10% w/w of baicalein and not less than 2% w/w of chrysin for use in the therapeutic management of hypertriglyceridemia, associated with chemotherapy and hyperglycemia.

Abstract: Disclosed are compositions containing not less than 10% w/w of oroxylin A, not less than 10% w/w of baicalein and not less than 2% w/w of chrysin for use in the therapeutic management of memory impairment and cognitive dysfunction. More specifically, the invention discloses the use of abovementioned compositions for the management of cognitive impairment induced by chemotherapy and hyperglycemia.

Abstract: Disclosed is a method for therapeutic management of hyperglycemia in mammals using compositions containing thymohydroquinone. More specifically, the invention discloses compositions containing thymohydroquinone for inhibiting the activity of the enzyme ?-glucosidase and increasing the cellular uptake of glucose by mammalian cells. The anti-oxidant, anti-inflammatory and anti-glycation effects of thymohydroquinone are also disclosed herein.

Abstract: A food composition for managing non-food allergies in companion animals is disclosed, along with a method of managing non-food allergies.

Abstract: Methods are provided to make clinoptilolite into a water-soluble hydrolyzed form suitable for various administration routes, including oral administration. Absorption of water-soluble hydrolyzed clinoptilolite fragments can aid in detoxification by binding heavy metals and environmental toxins, can reduce reactive oxygen species and inflammation related to heavy metals and other/environmental toxins, resulting in an increase in energy, and/or in an increase in one or more of focus, concentration, and memory. Water-soluble hydrolyzed clinoptilolite fragments can be combined with one or more dietary supplements, including various vitamins and sleep aids.

Abstract: The invention provides a method for improving the volume of hair which comprises the following steps: (i) treating the hair by topical application of a composition comprising from 1 to 25 wt % of one or more glucosamine salts; (ii) shaping the treated hair; (iii) allowing the composition to remain in contact with the shaped hair before drying. Advantageously the method of the invention does not require the breakage of the hair disulfide bonds, does not require the use of high temperature heated implements such as straightening irons, and can be accomplished by a consumer without intervention of a professional hairdresser.

Abstract: Foods or meals high in available carbohydrate such as sucrose or starch increase postprandial blood glucose concentrations. According to Node et al. (Cardiovascular diabetology, 8, 23 (2009)), repeated high post-prandial plasma glucose “spikes” are associated with an increased risk of developing type II diabetes. Unregulated glycemic excursions are undesirable, and any reduction or “blunting” of the post-prandial glucose concentration in blood is potentially beneficial. This invention relates to an edible composition for delay of intestinal glucose uptake through synergistic inhibition of both active sodium glucose co-transporter 1 (SGLT1) and passive glucose transporter 2 (GLUT2) leading to flattening or blunting of the post-prandial glucose peak.

Abstract: A pharmaceutical composition contains the chromone derivative of Chemical Formula 1 and a pharmaceutically acceptable salt as an active ingredient, thus effectively inhibiting the activation of EMT to thereby enable the effective suppression of a disease caused by fibrosis of an organ or tissue in vivo due to the activation of EMT.

Abstract: Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing Sirt1, Sirt3, or AMPK activity are provided herein. Such compositions comprise a combination of a PDE 5 inhibitor, such as sildenafil or icariin, and resveratrol, and a branched amino acid such as leucine, or its metabolite.

Abstract: Provided herein are trioxacarcin-antibody drug conjugates of Formula (A): and pharmaceutically acceptable salts thereof, comprising at least one instance of the group -L1-(A-L2)a-B attached thereto, wherein a is an integer between 1 and 10, inclusive, L1 is absent or is a linking group, A is a moiety formed from the reaction of two complimentary groups (X and Y), L2 is absent or is another linking group, and B is an antibody or antibody fragment. Also provided are methods of preparing these antibody-drug conjugates, pharmaceutically acceptable compositions thereof, and methods of their use and treatment. Further provided are precursors to the trioxacarcin-antibody drug conjugates, novel trioxacarcins without an antibody conjugated thereto, pharmaceutical compositions thereof, and methods of their use and treatment.

Abstract: The present disclosure relates to a coated implantable medical device, comprising: a base layer comprising mTOR inhibitor, and at least one biodegradable polymer; a middle layer comprising mTOR inhibitor, and at least one biodegradable polymer; and a top layer selected from the group consisting of hydrophilic polymer, and combination of hydrophilic polymer and antioxidant, wherein the total mTOR inhibitor concentration over the medical device is in the range of 0.7 to 3.00 ?g/mm2. The present disclosure further relates to a method of preparing a coated implantable medical device.

Abstract: Certain embodiments are directed to methods and compositions for treating obesity, diabetes, and/or cancer with a combination of ursolic acid and resveratrol.

Abstract: The present invention relates to a composition for preventing and treating muscle diseases or improving muscular function, containing, as an active ingredient, at least one selected from the group consisting of morusin, kuwanon G, and a Mori Cortex Radicis extract. The Mori Cortex Radicis extract, morusin, or kuwanon G, according to the present invention, has an effect of remarkably enhancing muscular function by increasing the expression of p-mTOR protein involved in muscular protein synthesis, inhibiting the expression of mRNAs of MuRF-1 and atrogin-1 involved in muscular protein degradation, and increasing the expression of mRNAs of MyoD and myogenin involved in muscular differentiation. In addition, the present invention is a natural product so as to be used safely without side effects, thereby being usable in drugs, food, or cosmetics.